EPRX Eupraxia Pharmaceuticals Inc.
Price Chart
Executive Summary
Eupraxia reported Q1 2026 EPS of -$0.37, a 91.5% miss vs consensus of -$0.19, with net loss widening to $12.7M from $6.8M a year ago due to doubled R&D costs. The company highlighted positive 36-week tissue health and symptom data from its RESOLVE trial and a $63.2M public offering, ending the quarter with $138.9M in cash and investments, sufficient into H2 2028.
Actionable Insight
The significant EPS miss and widening losses are bearish, but the strong cash position and positive clinical data may provide a floor. Monitor upcoming Phase 2b data readouts for EP-104GI; any efficacy or safety signals could drive volatility. The $63.2M offering at $7.00/share creates a reference price near current levels.
Key Facts
- Q1 2026 EPS of -$0.37 missed consensus of -$0.19 by 91.5%
- Net loss widened to $12.7M from $6.8M in Q1 2025, driven by doubled R&D costs for the RESOLVE trial
- Cash and investments totaled $138.9M as of March 31, 2026, up from $80.6M at year-end 2025
- Closed $63.2M public offering in February 2026, issuing 7.6M shares at $7.00/share
- Positive 36-week tissue health and symptom data reported from highest dose cohort in Phase 1b/2a RESOLVE trial for EoE
- Company expects cash runway into H2 2028
Financial Impact
EPS miss of $0.18 vs consensus; net loss increased by $5.9M YoY
Risk Factors
- Clinical trial failure or delays in RESOLVE trial
- Further dilution from warrant exercises or additional offerings
- Tariff impact on manufacturing costs
- Cash burn rate may accelerate if trials expand
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293518 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
14d ago
|
6-K
| $7.09 $6.33 | ▼ −10.72% | ▼ −10.43% | $6.04 (−14.81%) |
|
May 29, 2026
14d ago
|
6-K
| $7.09 $6.33 | ▼ −10.72% | ▼ −10.43% | $6.04 (−14.81%) |
|
May 28, 2026
15d ago
|
6-K
| $7.09 $5.95 | ▼ −16.08% | ▼ −13.56% | $6.04 (−14.81%) |
|
May 12, 2026
4w ago
|
Press Release
| $7.55 $6.29 | ▲ +16.69% | ▲ +15.53% | $6.04 (+20.00%) |
|
Apr 22, 2026
7w ago
|
6-K
| $7.06 $7.11 | ▲ +0.71% | ▲ +0.65% | $6.04 (−14.45%) |
|
Apr 21, 2026
7w ago
|
6-K
| $7.02 $7.11 | ▲ +1.28% | ▲ +0.20% | $6.04 (−13.96%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $7.02 $7.11 | ▲ +1.28% | ▲ +0.20% | $6.04 (−13.96%) |
|
Mar 13, 2026
13w ago
|
Press Release
| $7.36 $7.10 | ▼ −3.53% | ▼ −1.41% | $6.04 (−17.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access